Wyeth’s Tygacil sNDA For Community-Acquired Pneumonia Accepted By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company tells “The Pink Sheet” DAILY that tigecycline would address needs of patients resistant to other antibiotics, such as J&J’s Levaquin.
You may also be interested in...
Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.
Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.